Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in α-synuclein transgenic mice

BMC Neuroscience

Olga Corti⁵  Alexis Brice¹  Sophie Tezenas du Montcel²  Jiping Huang⁶  Robin Barbour⁶  John P Anderson⁶  Hilal A Lashuel⁷  Paul Blanche⁴  Marie-Paule Muriel⁵  Jérôme Garrigue⁵  Amandine Roux⁵  Margot Fournier³ 

[1] AP-HP, Hôpital de la Salpêtrière, Department of Genetics and Cytogenetics, F-75013 Paris, France;Department of Biostatistics and Medical Informatics, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux, 47 Boulevard de l'Hôpital, Paris F-75013 France;Current address: Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Prilly-Lausanne, CH 1008 Switzerland;Université Pierre et Marie Curie-Paris 6, ER4 Modeling in Clinical Research, Paris F-75013 France;CNRS, UMR 7225, F-75013, Paris, France;Elan Pharmaceuticals, 180 Oyster Point Blvd, South San Francisco, California, CA 94080 USA;Laboratory of Molecular Neurobiology and Chemical Biology of Neurodegeneration, Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne CH-1015 Switzerland

关键词: Parkinson’s disease;    parkin knockout mice;    Transgenic mice overproducing α-syn;    Posttranslational modifications;    Ubiquitin;    α-syn truncation;    α-syn phosphorylation;   

Others  :  1170576
DOI  :  10.1186/1471-2202-14-135

 received in 2013-05-27, accepted in 2013-10-28,  发布年份 2013

【 摘 要 】

Background

Mutations of the gene encoding the major component of Lewy bodies (LB), α-synuclein (α-syn), cause autosomal dominant forms of Parkinson’s disease (PD), whereas loss-of-function mutations of the gene encoding the multifunctional E3 ubiquitin-protein ligase Parkin account for autosomal recessive forms of the disease. Parkin overproduction protects against α-syn-dependent neurodegeneration in various in vitro and in vivo models, but it remains unclear whether this process is affected by Parkin deficiency. We addressed this issue, by carrying out more detailed analyses of transgenic mice overproducing the A30P variant of human α-syn (hA30Pα-syn) and with two, one or no parkin knockout alleles.

Results

Longitudinal behavioral follow-up of these mice indicated that Parkin depletion delayed disease-predictive sensorimotor impairment due to α-syn accumulation, in a dose-dependent fashion. At the end stage of the disease, neuronal deposits containing fibrillar α-syn species phosphorylated at S129 (P^S129α-syn) were the predominant neuropathological feature in hA30Pα-syn mice, regardless of their parkin expression. Some of these deposits colocalized with the LB markers ubiquitin and α-syn truncated at D135 (α-synD135), indicating that P^S129α-syn is subjected to secondary posttranslational modification (PTM); these features were not significantly affected by parkin dysfunction.

Conclusions

These findings suggest that Parkin deficiency acts as a protective modifier in α-syn-dependent neurodegeneration, without overtly affecting the composition and characteristics of α-syn deposits in end-stage disease.

【 授权许可】

   
2013 Fournier et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Oueslati A, Fournier M, Lashuel HA: Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res 2010, 183:115-145.
• [2]Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, et al.: Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006, 281(40):29739-29752.
• [3]Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T: Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002, 4(2):160-164.
• [4]Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG: Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 2003, 278(45):44405-44411.
• [5]Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VM, Trojanowski JQ, Mann D, Iwatsubo T: Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem 2002, 277(50):49071-49076.
• [6]Sampathu DM, Giasson BI, Pawlyk AC, Trojanowski JQ, Lee VM: Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am J Pathol 2003, 163(1):91-100.
• [7]Rott R, Szargel R, Haskin J, Shani V, Shainskaya A, Manov I, Liani E, Avraham E, Engelender S: Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J Biol Chem 2008, 283(6):3316-3328.
• [8]Nonaka T, Iwatsubo T, Hasegawa M: Ubiquitination of alpha-synuclein. Biochemistry 2005, 44(1):361-368.
• [9]Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T: Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998, 152(4):879-884.
• [10]Campbell BC, McLean CA, Culvenor JG, Gai WP, Blumbergs PC, Jakala P, Beyreuther K, Masters CL, Li QX: The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem 2001, 76(1):87-96.
• [11]Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, Dawson TM, Jakala P, Hartmann T, Price DL, et al.: Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A 2005, 102(6):2162-2167.
• [12]Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ: A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem 2005, 280(24):22670-22678.
• [13]Chen L, Periquet M, Wang X, Negro A, McLean PJ, Hyman BT, Feany MB: Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 2009, 119(11):3257-3265.
• [14]Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, Ross CA, Dawson VL, Dawson TM: Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 2001, 7(10):1144-1150.
• [15]Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D: Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 2007, 130(Pt 3):799-815.
• [16]Fournier M, Vitte J, Garrigue J, Langui D, Dullin J-P, Saurini F, Hanoun N, Perez-Diaz F, Cornilleau F, Joubert C, et al.: Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy. PLoS One 2009, 4(8):e6629.
• [17]Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM: Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34(4):521-533.
• [18]Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL: Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 - > Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A 2002, 99(13):8968-8973.
• [19]Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P: Alpha - synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A 2002, 99(16):10813-10818.
• [20]Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L: Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287(5456):1265-1269.
• [21]Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, Odoy S, Fujiwara H, Hasegawa M, et al.: Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 2002, 110(10):1429-1439.
• [22]Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T: Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci 2011, 31(46):16884-16894.
• [23]van der Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WP, Ruegg MA, et al.: Neuropathology in mice expressing human alpha-synuclein. J Neurosci 2000, 20(16):6021-6029.
• [24]Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H: Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 2004, 91(2):451-461.
• [25]Corti O, Lesage S, Brice A: What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 2011, 91(4):1161-1218.
• [26]Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denefle P, Wood NW, et al.: Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000, 342(21):1560-1567.
• [27]Dawson TM, Dawson VL: The role of parkin in familial and sporadic Parkinson's disease. Mov Disord 2010, 25(Suppl 1):S32-39.
• [28]Haywood AF, Staveley BE: Parkin counteracts symptoms in a Drosophila model of Parkinson's disease. BMC Neurosci 2004, 5:14. BioMed Central Full Text
• [29]Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J, et al.: Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002, 36(6):1007-1019.
• [30]Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B: Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 2003, 37(6):911-924.
• [31]von Coelln R, Thomas B, Andrabi SA, Lim KL, Savitt JM, Saffary R, Stirling W, Bruno K, Hess EJ, Lee MK, et al.: Inclusion body formation and neurodegeneration are parkin-independent in a mouse model of alpha-synucleinopathy. J Neurosci 2006, 26(14):3685-3696.
• [32]Kahle PJ, Neumann M, Ozmen L, Muller V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, et al.: Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 2001, 159(6):2215-2225.
• [33]Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, Laville M, Pratt J, Corti O, Pradier L, et al.: Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 2003, 12(18):2277-2291.
• [34]Vitte J, Traver S, Maues De Paula A, Lesage S, Rovelli G, Corti O, Duyckaerts C, Brice A: Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J Neuropathol Exp Neurol 2010, 69(9):959-972.
• [35]Jan C, Muriel MP, Rolland AS, Hirsch EC, Francois C: Localization of D1a dopamine receptors on cell bodies and axonal endings in the substantia nigra pars reticulata of the rat. J Neural Transm 2007, 114(12):1509-1517.
• [36]Thingholm TE, Larsen MR: The use of titanium dioxide micro-columns to selectively isolate phosphopeptides from proteolytic digests. Methods Mol Biol 2009, 527:57-66. xi
• [37]Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M, Olschewski D, Yin G, Zweckstetter M, Masliah E, et al.: Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem 2010, 285(4):2807-2822.
• [38]Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA, Lansbury PT Jr, Fernandez CO, Eliezer D, Zweckstetter M, et al.: Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem 2008, 283(24):16895-16905.
• [39]Inglis KJ, Chereau D, Brigham EF, Chiou SS, Schobel S, Frigon NL, Yu M, Caccavello RJ, Nelson S, Motter R, et al.: Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem 2009, 284(5):2598-2602.
• [40]Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA: Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 2001, 21(24):9549-9560.
• [41]Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, Sawa A, LD V, Dawson TM, Ross CA: Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 2001, 10(9):919-926.
• [42]Lewis KA, Yaeger A, DeMartino GN, Thomas PJ: Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations. J Bioenerg Biomembr 2010, 42(1):85-95.
• [43]Choubey V, Safiulina D, Vaarmann A, Cagalinec M, Wareski P, Kuum M, Zharkovsky A, Kaasik A: Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem 2011, 286(12):10814-10824.